Circulating Fibrocytes in Non-small Cell Lung Cancer.

Chang Gung Medical Foundation

Status: Unknown

Conditions: NSCLC

Study type: Observational

Funder types: Other

Identifiers

NCT01998425

IRB100-2929B-FibLC-CGMH

Details and patient eligibility

About

The investigators will collect fibrocytes (CD45+Col-1+) in patients with non-small cell lung cancer (NSCLC). The investigators hypothesize that patients with NSCLC experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in NSCLC patients.

Full description

Fibrocytes have been described in both mice and humans, where they bear a hematopoietic progenitor phenotype (CD45+Col-1+). Fibrocytes have previously been described in murine cancer, implicated as mediators of tumor immune escape. In this study, the investigators will collect fibrocytes including CD45+Col-1+ expression. The cells express indoleamine oxidase, which is primarily responsible for their immunosuppressive properties. The investigators hypothesize that patients with non-small cell lung cancer experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in non-small cell lung cancer patients.

Enrollment: 60 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

Exclusion criteria

• Combination of other malignancy.
• Age less than 20 years (not include 20 years).
• Pregnancy.

Trial design

60 participants in 1 patient group

Non-small cell lung cancer

Description:

The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.